We investigated the carriage of serogroup W135 meningococci and its relationship with protective immunity in Niamey. Between February and May 2003, three oropharyngeal swabs and two serum samples were each taken from 287 school children. Serogroup W135 isolates were obtained from 8.9% of children. Specific IgG > or = 2 microg/ml using ELISA or serum bactericidal assay (SBA) titre > or = 8 were supposed to represent the protective immunity to a serogroup. The proportion of children with serogroup W135-specific IgG > or = 2 microg/ml increased significantly during follow-up (13.9% to 19.1%), but not the proportion of those with SBA titre > or = 8 (10.1% to 11.6%). At the end of the follow-up, we observed a significant association between carriage of serogroup W135 strains and presumed protective immunity to this serogroup, using either ELISA or SBA. Among 240 children having an initial SBA titre < 8, 20 carried serogroup W135 strains at least once. In May, 25% of carriers had an SBA titre > or = 8, vs. 2.3% of non-carriers. For ELISA, 230 children had specific IgG < 2 microg/ml in February, with 22 having at least one swab positive for serogroup W135 meningococci later. In May, 45.5% of them had specific IgG > or = 2 microg/ml vs. 5.3% among non-carriers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.micinf.2006.03.006 | DOI Listing |
Andes Pediatr
June 2024
Universidad San Sebastián, Santiago, Chile.
Unlabelled: Since 1941, outbreaks of Neisseria meningitidis have been recorded in Chile which, to date, have varied according to clinical form, incidence, lethality, and the responsible serogroup.
Objective: To summarize the available evidence on the epidemiological profile of acute bacterial meningitis due to Neisseria meningitidis in Chile, analyzing the incidence between 1990 and 2019.
Method: A systematized review of primary articles was carried out following the Cochrane Collaboration standards.
Vaccine
October 2024
International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address:
Meningococcal disease is caused by Neisseria meningitidis or meningococcus. Every year globally around 1.2 million people are affected and approximately 120,000 deaths occur due to meningitis.
View Article and Find Full Text PDFVaccine
April 2024
Lanzhou Institute of Biological Products Co., Ltd., Lanzhou 730046, China. Electronic address:
Investigating the mechanisms by which W135 meningococcal conjugate (PSW135-TT) activates adaptive immune responses in mice can provide a comprehensive understanding of the immune mechanisms of bacterial polysaccharide conjugate vaccines. We compared B-cell and T-cell immune responses immunized with W135 meningococcal capsular polysaccharides (PSW135), tetanus toxoid (TT) and PSW135-TT in mice. The results showed that PSW135-TT could induce higher PSW135-specific and TT-specific IgG antibodies with a significant enhancement after two doses.
View Article and Find Full Text PDFCureus
November 2023
Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
In healthy people, (the meningococcus) is a typical component of the nasopharyngeal microbiome, but in those who are susceptible, it can cause septicemia and meningitis. This section gives a general overview of the meningococcus types and the sickness induced by Evaluate genes for phase-changeable adhesions, virulence factors, and effective colonization of the human host. In our final section, we summarize the evolution of meningococcal vaccines and their current state while emphasizing the value of ongoing molecular research into the pathogen's epidemiology and structural analysis of its antigens.
View Article and Find Full Text PDFAfr J Lab Med
November 2023
Department of Medical Microbiology, Faculty of Clinical Sciences, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria.
Background: Within the African meningitis belt, yearly outbreaks of cerebrospinal meningitis (CSM), with incidence rates of 10-100 cases per 100 000 population, are typically punctuated by explosive epidemics occurring every 8-12 years, with incidence rates that can exceed 1000 cases per 100 000 population. From 1928 to 2018, Nigeria recorded the highest number (21%) of cases in the region. The reactive vaccination strategy, a protocol with major drawbacks, has been the vaccination method utilised in Nigeria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!